Your browser is no longer supported. Please, upgrade your browser.
Settings
CLVS Clovis Oncology, Inc. daily Stock Chart
CLVS [NASD]
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-8.28 Insider Own0.40% Shs Outstand48.59M Perf Week8.39%
Market Cap3.04B Forward P/E- EPS next Y-3.38 Insider Trans-17.40% Shs Float47.46M Perf Month-6.60%
Income-365.20M PEG- EPS next Q-1.29 Inst Own- Short Float14.65% Perf Quarter-11.66%
Sales38.50M P/S78.92 EPS this Y7.40% Inst Trans3.43% Short Ratio5.13 Perf Half Y-1.23%
Book/sh6.12 P/B10.22 EPS next Y55.70% ROA-57.10% Target Price89.73 Perf Year67.60%
Cash/sh12.92 P/C4.84 EPS next 5Y- ROE-179.60% 52W Range35.38 - 99.45 Perf YTD40.77%
Dividend- P/FCF- EPS past 5Y-29.60% ROI- 52W High-37.12% Beta1.44
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin81.90% 52W Low76.74% ATR2.95
Employees278 Current Ratio3.20 Sales Q/Q- Oper. Margin- RSI (14)43.21 Volatility4.89% 4.66%
OptionableYes Debt/Eq0.94 EPS Q/Q27.30% Profit Margin- Rel Volume0.69 Prev Close62.90
ShortableYes LT Debt/Eq0.94 EarningsNov 01 AMC Payout- Avg Volume1.35M Price62.53
Recom2.10 SMA201.09% SMA50-12.23% SMA200-10.43% Volume938,426 Change-0.59%
Oct-23-17Initiated Barclays Overweight $105
Sep-15-17Initiated RBC Capital Mkts Sector Perform $81
Aug-17-17Initiated Evercore ISI In-line $73
Jul-07-17Initiated Gabelli & Co Buy $125
Jun-23-17Initiated Oppenheimer Perform
Jun-20-17Upgrade Janney Neutral → Buy
Jun-19-17Upgrade Chardan Capital Markets Sell → Neutral $36 → $50
Jun-16-17Resumed Credit Suisse Outperform
Jun-13-17Initiated Leerink Partners Outperform $85
May-17-17Upgrade JP Morgan Neutral → Overweight
Feb-03-17Downgrade Chardan Capital Markets Neutral → Sell $36
Jan-27-17Initiated BofA/Merrill Buy $74
Jan-26-17Upgrade Piper Jaffray Neutral → Overweight
Jan-23-17Reiterated Stifel Buy $52 → $86
Jan-13-17Initiated Morgan Stanley Overweight
Dec-21-16Reiterated WallachBeth Hold $22 → $49
Dec-20-16Upgrade Chardan Capital Markets Sell → Neutral $15 → $36
Oct-25-16Initiated Chardan Capital Markets Sell $15
Sep-23-16Reiterated SunTrust Buy $38 → $50
Sep-21-16Upgrade Credit Suisse Neutral → Outperform
Dec-06-17 03:09PM  Clovis' sNDA for Rubraca Gets Priority Review in the U.S. Zacks
02:08PM  Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down Investor's Business Daily
09:30AM  Clovis Up On Priority Review Status for Ovarian Cancer Therapy -- Biotech Movers TheStreet.com
09:30AM  Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover TheStreet.com
07:46AM  Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data Zacks
Dec-05-17 08:25PM  Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug American City Business Journals
04:05PM  Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application Business Wire
Nov-28-17 11:58AM  Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte Forbes
Nov-27-17 08:04AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Nov-24-17 11:24AM  3 Companies Competing to Gain Lead in Ovarian Cancer Market Zacks
Nov-21-17 10:25AM  TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU Zacks
08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Nov-20-17 08:20AM  Todays Research Reports on Trending Tickers: Ekso Bionics and Clovis Oncology ACCESSWIRE
Nov-15-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Nov-14-17 02:55PM  CORRECTING and REPLACING Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-13-17 06:45PM  Edited Transcript of CLVS earnings conference call or presentation 1-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
07:50AM  Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-08-17 06:40PM  Clovis Oncology to Present at the Stifel 2017 Healthcare Conference Business Wire
01:45PM  Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : November 8, 2017 Capital Cube
07:40AM  Corporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and Nivolumab ACCESSWIRE
Nov-02-17 11:49AM  Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss Zacks
Nov-01-17 06:26PM  Clovis reports 3Q loss Associated Press
05:47PM  Neurocrine, Exelixis, Juno Stocks Rocket After Crushing Views Investor's Business Daily
04:05PM  Clovis Oncology Announces Third Quarter 2017 Operating Results Business Wire
12:00PM  Clovis Oncology, Inc. to Host Earnings Call ACCESSWIRE
Oct-30-17 11:13AM  What's in the Cards for Immune Design (IMDZ) in Q3 Earnings? Zacks
Oct-26-17 12:16PM  Allergan (AGN) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-25-17 10:23AM  Clovis Oncology, Inc. Value Analysis (NASDAQ:CLVS) : October 25, 2017 Capital Cube
07:00AM  Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors CNW Group
Oct-24-17 08:14AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : October 24, 2017 Capital Cube
Oct-23-17 08:00AM  Clovis Oncology to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 1 Business Wire
Oct-17-17 08:39AM  Gilead Sciences on the Street: Analyst Recommendations in October Market Realist
08:05AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Oct-16-17 08:04AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Oct-11-17 08:07AM  Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit Zacks
Oct-10-17 10:50AM  Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca Zacks
Oct-09-17 04:05PM  Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer Business Wire
Oct-06-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Oct-05-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Oct-04-17 11:40AM  Cancer-Cure Makers Make Great Takeover Stocks Forbes
Oct-03-17 04:22PM  These Biotechs Slump As Report Suggests Discounting Their Drugs Investor's Business Daily
Sep-28-17 03:00AM  Clovis Oncology Scores Relative Strength Rating Upgrade Investor's Business Daily
Sep-26-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Sep-25-17 08:10AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : September 25, 2017 Capital Cube
Sep-19-17 08:51AM  Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Dimension Therapeutics and Clovis Oncology ACCESSWIRE
Sep-18-17 04:02PM  Clovis Up 10% On Double Normal Volume Forbes +10.48%
03:44PM  So Much PARP Inhibitor Deal Hype, So Little Payoff Bloomberg
Sep-13-17 06:00AM  Clovis Oncologys Rucaparib ARIEL3 Study Data Published in The Lancet Business Wire
Sep-12-17 03:08PM  Should You Keep Your Portfolio Healthy with Biotech ETFs? Zacks
Sep-11-17 08:00AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology ACCESSWIRE
06:30AM  A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It Forbes
Sep-08-17 10:39AM  Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers TheStreet.com -7.12%
Sep-07-17 06:05PM  Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017 Business Wire
04:18PM  Why Clovis Oncology Fell 7.1% in August Motley Fool
05:12AM  Clovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound? Zacks
Sep-06-17 08:01AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Sep-02-17 10:20AM  Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition TheStreet.com
Aug-30-17 02:58PM  After Gilead's Acquisition Of KITE, Who Gets Gobbled Up Next? Forbes
08:00AM  Clovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress Business Wire
Aug-23-17 04:59PM  Here's Why Clovis Stock Is Up Almost 60% So Far in 2017 Zacks
08:04AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Aug-18-17 06:33PM  Tesaro: Losing Its Edge? Barrons.com
04:27PM  Ovarian Cancer Market Still Up For Grabs Barrons.com
07:39AM  Analysts Recommendations for Bristol-Myers Squibb in August 2017 Market Realist
Aug-16-17 08:16PM  Clovis Oncology, Inc. Value Analysis (NASDAQ:CLVS) : August 17, 2017 Capital Cube
08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Aug-15-17 09:20AM  Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses Zacks
Aug-14-17 08:01AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Aug-13-17 08:10AM  Edited Transcript of CLVS earnings conference call or presentation 2-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-12-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Aug-11-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Aug-10-17 08:04AM  IHS Markit Score Update: Drop in demand for ETFs holding Clovis Oncology Inc is a negative sign for its shares Markit
Aug-09-17 09:02AM  Biotech: Why Clovis And Tesaro Look Well Positioned Barrons.com -6.11%
Aug-08-17 02:36PM  A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision Benzinga
Aug-04-17 09:52AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : August 4, 2017 Capital Cube
Aug-03-17 11:47AM  One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce? TheStreet.com -5.12%
09:57AM  Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses Zacks
Aug-02-17 10:57PM  Clovis reports 2Q loss Associated Press
04:05PM  Clovis Oncology Announces Second Quarter 2017 Operating Results Business Wire
10:50AM  Investor Network: Clovis Oncology, Inc. to Host Earnings Call ACCESSWIRE
Jul-31-17 04:51PM  Why Clovis Oncology Tumbled 13.5% Today Motley Fool -13.48%
04:30PM  Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today Motley Fool
04:11PM  Why Clovis, Regeneron Are Leading A Biotech Deluge Today Investor's Business Daily
01:45PM  Clovis Sell-Off May Be Overdone TheStreet.com
12:10PM  Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why TheStreet.com
08:00AM  Today's Research Reports on Trending Tickers: Clovis Oncology Inc. and Intercept Pharmaceuticals Inc. ACCESSWIRE
07:10AM  Bristol-Myers and Clovis will partner for cancer combination trials MarketWatch
06:59AM  Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types Business Wire
Jul-27-17 04:14PM  How AstraZeneca Failed Not Once But Twice In Cancer Drugs Investor's Business Daily +5.51%
Jul-18-17 09:05AM  3 Stocks at 52-Week Highs Still Worth Buying Motley Fool
Jul-13-17 05:37PM  Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion Zacks
Jul-07-17 07:43AM  Here's Why Clovis Oncology Inc. Jumped 70% in June Motley Fool
Jun-30-17 04:14PM  This Rebounding Pharma Stock May Launch Another Breakout Move Investor's Business Daily
Jun-29-17 10:41AM  3 Stocks That Turned $8,000 Into at Least $25,600 in Just One Year Motley Fool
Jun-27-17 03:43PM  Is It Too Late to Buy Clovis Oncology Stock? Motley Fool
07:02AM  Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race? Motley Fool
Jun-26-17 02:52PM  Seattle Genetics: A Disappointing StudyOr Was It? Barrons.com
Jun-23-17 03:40PM  3 Growth Stocks for Bright Investors Motley Fool
09:00AM  Healthcare ETF (IYH) Hits New 52-Week High Zacks
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier; and a clinical collaboration with Bristol-Myers Squibb Company to evaluate combination of Opdivo (Nivolumab) and Rubraca (rucaparib) in Phase 2 and pivotal Phase 3 clinical trials in multiple tumor types. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPICKSCHEN THORLEFDirectorDec 08Sale60.004,500270,00025,618Dec 08 09:32 PM
IVERS-READ GILLIAN CSee RemarksNov 15Sale63.703,000191,100185,583Nov 16 04:45 PM
IVERS-READ GILLIAN CSee RemarksOct 16Sale84.543,000253,620188,583Oct 17 08:13 PM
IVERS-READ GILLIAN CSee RemarksSep 15Sale69.503,000208,500191,583Sep 18 04:35 PM
IVERS-READ GILLIAN CSee RemarksAug 15Sale70.053,000210,150194,583Aug 15 04:53 PM
BLAIR JAMES CDirectorAug 04Sale78.6118,4501,450,35517,056Aug 08 04:03 PM
IVERS-READ GILLIAN CSee RemarksJul 17Sale91.563,000274,680197,583Jul 17 06:07 PM
IVERS-READ GILLIAN CSee RemarksJun 15Sale61.823,000185,460200,583Jun 15 05:42 PM
IVERS-READ GILLIAN CSee RemarksMay 15Sale47.393,000142,170203,583May 15 06:24 PM
IVERS-READ GILLIAN CSee RemarksApr 17Sale56.023,000168,060206,583Apr 17 06:04 PM
IVERS-READ GILLIAN CSee RemarksMar 15Sale66.993,000200,970209,583Mar 15 05:15 PM